John R Forsayeth
Overview
Explore the profile of John R Forsayeth including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
736
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chao C, Blecha J, Polvoy I, Nillo R, Seo Y, Wilson D, et al.
Nucl Med Biol
. 2025 Feb;
142-143:108992.
PMID: 39913962
Objective And Background: The objective of this first-in-human study was to investigate the radiosynthesis, and the preliminary safety, biodistribution, and organ radiation dosimetry of the positron emission tomography (PET) imaging...
2.
Ford M, George B, Van Laar V, Holleran K, Naidoo J, Hadaczek P, et al.
Nat Med
. 2023 Aug;
29(8):2030-2040.
PMID: 37580533
Alcohol use disorder (AUD) exacts enormous personal, social and economic costs globally. Return to alcohol use in treatment-seeking patients with AUD is common, engendered by a cycle of repeated abstinence-relapse...
3.
Watkins L, Chavez R, Landry R, Fry M, Green-Fulgham S, Coulson J, et al.
Brain Behav Immun
. 2020 Aug;
90:155-166.
PMID: 32800926
Osteoarthritis results in chronic pain and loss of function. Proinflammatory cytokines create both osteoarthritis pathology and pain. Current treatments are poorly effective, have significant side effects, and have not targeted...
4.
Grace P, Loram L, Christianson J, Strand K, Flyer-Adams J, Penzkover K, et al.
Brain Behav Immun
. 2016 May;
59:49-54.
PMID: 27189037
Relapsing-remitting multiple sclerosis is commonly associated with motor impairments, neuropathic pain, fatigue, mood disorders, and decreased life expectancy. However, preclinical pharmacological studies predominantly rely on clinical scoring of motor deficit...
5.
Chen P, Ozawa T, Drummond D, Kalra A, Fitzgerald J, Kirpotin D, et al.
Neuro Oncol
. 2012 Dec;
15(2):189-97.
PMID: 23262509
Background: Liposomal drug packaging is well established as an effective means for increasing drug half-life, sustaining drug activity, and increasing drug efficacy, whether administered locally or distally to the site...
6.
7.
Richardson R, Kells A, Rosenbluth K, Salegio E, Fiandaca M, Larson P, et al.
Mol Ther
. 2011 Feb;
19(6):1048-57.
PMID: 21343917
Clinical trials involving direct infusion of neurotrophic therapies for Parkinson's disease (PD) have suffered from poor coverage of the putamen. The planned use of a novel interventional-magnetic resonance imaging (iMRI)...
8.
Conklin B, Hsiao E, Claeysen S, Dumuis A, Srinivasan S, Forsayeth J, et al.
Nat Methods
. 2008 Aug;
5(8):673-8.
PMID: 18668035
We are creating families of designer G protein-coupled receptors (GPCRs) to allow for precise spatiotemporal control of GPCR signaling in vivo. These engineered GPCRs, called receptors activated solely by synthetic...
9.
Fiandaca M, Forsayeth J, Dickinson P, Bankiewicz K
Neurotherapeutics
. 2008 Jan;
5(1):123-7.
PMID: 18164491
Convection-enhanced delivery (CED) of substances within the human brain is becoming a more frequent experimental treatment option in the management of brain tumors, and more recently in phase 1 trials...
10.
Forsayeth J, Eberling J, Sanftner L, Zhen Z, Pivirotto P, Bringas J, et al.
Mol Ther
. 2006 Jun;
14(4):571-7.
PMID: 16781894
The main medication for idiopathic Parkinson disease is L-Dopa. Drug efficacy declines steadily in part because the converting enzyme, aromatic L-amino acid decarboxylase (AADC), is lost concomitant with substantia nigra...